RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27130-27145

  Qin, Yu ^a   Chen, Wangbing ^b,c   Xiao, Yao ^a   Yu, Wendan ^a   Cai, Xin ^a   Dai, Meng ^a   Xu, Tingting ^a   Huang, Wenlin ^b,d   Guo, Wei ^b,d   Deng, Wuguo ^b,d   Wu, Taihua ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Guangzhou Double Bioproduct Inc   (China)

Author keywords

CBP; hTERT; Lung cancer; RFPL3

Indexed keywords

BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; PROTEIN RFPL3; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; BONE SIALOPROTEIN (35-62), HUMAN; CARRIER PROTEIN; PEPTIDE FRAGMENT; RFPL3 PROTEIN, HUMAN; SIALOGLYCOPROTEIN; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ADENOCARCINOMA; AGED; CELL PROLIFERATION; CELL SURVIVAL; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RNA, SMALL INTERFERING; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; TELOMERASE; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84944452186     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4825     Document Type: Article

References (48)

1. Blasco MA, Hahn WC. Evolving views of telomerase and cancer. Trends Cell Biol. 2003; 13:289-294.
2. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. 1998; 12:1073-1085.
3. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999; 5:1164-1170.
4. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279:349-52.
5. Morin GB. The human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989; 59:521-529.
6. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003; 194:221-33.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266:2011-15.
8. Harley CB. Telomerase and cancer therapeutics. Nat Rev. Cancer. 2008; 8:167-179.
9. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007; 30:123-129.
10. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol. 2007; 25:2727-2734.
11. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 1998; 58:622-625.
12. Lai SR, Cunningham AP, Huynh VQ, Andrews LG, Tollefsbol TO. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp Cell Res. 2007; 313:322-30.
13. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet. 2002; 12:80-85.
14. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate www.impactjournals.com/oncotarget 27144 Oncotarget transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000; 28:669-677.
15. Deng WG, Jayachandran G, Wu G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancerbinding protein-2beta in human lung cancer cells. J Biol Chem. 2007; 282:26460-70.
16. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor mediates upregulation of telomerase (hTERT). Mol Cell Biol. 2004; 24:6076-83.
17. Glasspool RM, Burns S, Hoare SF, Svensson C, Keith WN. The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes. Neoplasia. 2005; 7:614-22.
18. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem. 2004; 279:50976-85.
19. Chen W, Lu J, Qin Y, Wang J, Tian Y, Shi D, Wang S, Xiao Y, Dai M, Liu L, Wei G, Wu T, Jin B, et al. Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells. Oncotarget. 2014; 5:11909-23.
20. Shikama N. The p300/CBP family:integrating signals with transcription factors and chromatin. Trends Cell Biol. 1997; 7:230-236.
21. Giordano A, Avantaggiati ML. p300 and CBP: partners for life and death. J. Cell. Physiol. 1999; 181:218-230.
22. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14:1553-1577.
23. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23:4225-4231.
24. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001; 114:2363-2373.
25. Guo W, Lu J, Dai M, Wu T, Yu Z, Wang J, Chen W, Shi D, Yu W, Xiao Y, Yi C, Tang Z, Xu T, et al. Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers. Oncotarget. 2014; 5:9349-61.
26. Karamouzis MV, Papavassiliou AG. Retinoid receptor cross-talk in respiratory epithelium cancer chemoprevention. Trends Mol Med. 2005; 11:10-16.
27. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996; 384:641-643.
28. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol. 2004; 68:1145-1155.
29. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA. 1999; 96:14276-14281.
30. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999; 13:2388-2399.
31. Eyal Seroussi, Darek Kedra, Hua-Qin Pan, Peyrard M, Schwartz C, Scambler P, Donnai D, Roe BA, Dumanski JP. Duplications on Human Chromosome 22 Reveal a Novel Ret Finger Protein-Like Gene Family with Sense and Endogenous Antisense Transcripts. Genome Res. 1999; 9:803-814.
32. Henry J, Ribouchon M, Depetris D, Matteï M, Offer C, Tazi-Ahnini R, Pontarotti P. Cloning, structural analysis, and mapping of the B30 and B7 multigenic families to the major histocompatibility complex (MHC) and other chromosomal regions. Immunogenetics. 1997; 46:383-395.
33. Takahashi M, Inaguma Y, Hiai H, Hirose F. Developmentally regulated expression of a human "finger"- containing gene encoded by the 58 half of the ret transforming gene. Mol Cell Biol. 1988; 8:1853-1856.
34. Bonnefont J, Nikolaev SI, Perrier AL, Guo S, Cartier L, Sorce S, Laforge T, Aubry L, Khaitovich P, Peschanski M, Antonarakis SE, Krause KH. Evolutionary forces shape the human RFPL1, 2, 3 genes toward a role in neocortex development. American journal of human genetics. 2008; 83:208-218.
35. Assou S, Boumela I, Haouzi D, Monzo C, Dechaud H, Kadoch IJ, Hamamah S. Transcriptome analysis during human trophectoderm specification suggests new roles of metabolic and epigenetic genes. PloS one. 2012; 7:e39306.
36. Bonnefont J, Laforge T, Plastre O, Beck B, Sorce S, Dehay C, Krause KH. Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation. Cell death and differentiation. 2011; 18:293-303.
37. Tan BH1, Suzuki Y, Takahashi H, Ying PH, Takahashi C, Han Q, Chin WX, Chao SH, Sawasaki T, Yamamoto N, Suzuki Y. Identification of RFPL3 Protein as a Novel E3 Ubiquitin Ligase Modulating the Integration Activity of Human Immunodeficiency Virus, Type 1 Preintegration Complex Using a Microtiter Plate-based Assay. J Biol Chem. 2014; 289:26368-82.
38. Lupas A, Van DM, Stock J. Predicting coiled coils from protein sequences. Science. 1991; 252:1162-1164.
39. Borden KL, Freemont PS. The RING finger domain: A recent example of a sequence-structure family. Curr Opin Struct Biol. 1996; 6:395-401.
40. Borden KL, Lally JM, Martin SR, O'Reilly NJ, Solomon E, Freemont PS. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia proto oncoprotein PML. Proc Natl Acad Sci. 1996; 93:1601-1606.
41. Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, Yu W, Dai M, Li Z, Yi C, Zhao S, Li M, Du S, et al. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget. 2015; 6:8046-61. www.impactjournals.com/oncotarget 27145 Oncotarget
42. Shikama N, Chan HM, Krstic-Demonacos M, Smith L, Lee CW, Cairns W, La Thangue NB. Functional interaction between nucleosome assembly proteins and p300/ CREBbinding protein family coactivators. Mol Cell Biol. 2000; 20:8933-8943.
43. Brownell JE, Allis CD. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev. 1996; 6:176-184.
44. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997; 389:349-352.
45. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 1993; 72:73-84.
46. Gu W, Roeder RG. Synergistic activation of transription by CBP and p53. Nature. 1997a; 387:819-822.
47. Martinez-Balbás MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F-1 activity by acetylation. EMBO J. 2000; 19:662-271.
48. Shi D, Xie F, Zhang Y, et al. TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF- 1alpha signaling pathway. Cancer Prev Res (Phila). 2014; 7:266-277.